fintopic.
Docs Get the API

FDA rejects Summit Therapeutics' lung cancer drug ivonescimab

8 statements from 7 sources, Nov 15, 2026 12:00 UTC to Nov 16, 2026 15:48 UTC
News
Updated
SMMT
Front page

Statements (8)

  1. Bearish

    Summit Therapeutics shares dropped after the FDA declined to approve its lung cancer drug ivonescimab.

    economictimes.indiatimes.comHigh importance
  2. Bearish

    Summit Therapeutics stock crashed after the FDA rejected its lung cancer drug ivonescimab.

    investors.comHigh importance
  3. Bearish

    Astra Zeneca's partner Summit Therapeutics received a cold call from the FDA regarding market approval for cancer drug ivonescimab.

    di.seHigh importance
  4. Bearish

    The FDA declined to approve a cancer drug for Summit Therapeutics

    marketwatch.comHigh importance
  5. Bearish

    FDA did not approve Summit Therapeutics' China-developed lung cancer drug ivonescimab due to lack of statistically significant survival benefit.

    investors.comHigh importance
  6. Bearish

    FDA rejects ivonescimab treatment for lung cancer developed by Summit Therapeutics

    statnews.comHigh importance
  7. Bearish

    FDA rejected ivonescimab, a lung cancer treatment from Summit Therapeutics and Akeso

    endpoints.newsHigh importance
  8. Neutral

    FDA issued a Complete Response Letter regarding the BLA for ivonescimab in combination with platinum-containing chemotherapy for Summit Therapeutics

    businesswire.comHigh importance